DANIEL CZARNOWSKI: Open Payments
NPI 1770107195 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,357 in 58 payments from 18 companies in 2025. Trend: 2023 $2,065 · 2024 $2,103 · 2025 $1,357
Food & beverage: $1,357
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 16 | $373 |
| Novartis Pharmaceuticals Corporation | 5 | $104 |
| Myriad Genetic Laboratories, Inc. | 1 | $101 |
| ARRAY BIOPHARMA INC | 5 | $97 |
| Fresenius Kabi USA, LLC | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $87 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $85 |
| Daiichi Sankyo Inc. | 3 | $79 |
| Merck Sharp & Dohme LLC | 3 | $61 |
| PFIZER INC. | 2 | $55 |
Products named: CALQUENCE, ENHERTU, MYRISK, BRAFTOVI, Stimufend, Nubeqa, Fabhalta, Xtandi.
Industry payments across IL — which companies pay providers there.
